Inosine ( DrugBank: Inosine )

5 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	4
6	Parkinson disease	8
13	Multiple sclerosis/Neuromyelitis optica	2
17	Multiple system atrophy	1
122	Superficial siderosis	1

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03168711 (ClinicalTrials.gov)	October 1, 2017	24/5/2017	Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Inosine;Drug: Placebo	Massachusetts General Hospital	The Salah Foundation;MGH cure ALS Fund	Completed	18 Years	85 Years	All	23	Phase 2	United States
2	JPRN-UMIN000029308	2017/07/18	30/09/2018	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of patients with amyotrophic lateral sclerosis with febuxostat and inosine in combination.	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of patients with amyotrophic lateral sclerosis with febuxostat and inosine in combination. - Effect of febuxostat and inosine on amyotrophic lateral sclerosis	Amyotrophic lateral sclerosis	Febuxostat 20 mg, Inosine 500 mg, twice a day for 14 days	Teikyo University	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	3	Not applicable	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. - Effect of febuxostat and inosine on CNS diseases	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
4	NCT02288091 (ClinicalTrials.gov)	January 2015	5/11/2014	A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)	A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: Inosine	Massachusetts General Hospital	The Salah Foundation;MGH cure ALS Fund	Completed	18 Years	N/A	All	32	Phase 1	United States

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat and inosine	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Complete	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
2	JPRN-UMIN000030930	2018/01/29	01/01/2019	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease. - Effect of febuxostat and inosine on Parkinson's disease	Parkinson's disease	Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days	StaGen Co. Ltd.	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	30	Not selected	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. - Effect of febuxostat and inosine on CNS diseases	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
4	NCT02642393 (ClinicalTrials.gov)	June 2016	19/12/2015	Study of Urate Elevation in Parkinson's Disease, Phase 3	A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease	Parkinson's Disease	Drug: Inosine;Drug: Placebo	Michael Alan Schwarzschild	The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester;National Institute of Neurological Disorders and Stroke (NINDS)	Completed	30 Years	N/A	All	298	Phase 3	United States;Puerto Rico
5	JPRN-UMIN000009062	2016/05/30	09/10/2012	An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease	An open-label, single-centered, non-randomized trial of inosine to assess its safety for patients with Parkinson's disease - An evaluation of the safety of inosine for patients with Parkinson's disease	Parkinson's disease	Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL	Dept. of Clinical pharmacology and Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Phase 1	Japan
6	JPRN-jRCTs061180060	22/03/2016	18/03/2019	Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease	Parkinson's disease;D010300	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)	Nagai Masahiro	NULL	Complete	>= 20age old	Not applicable	Both	100	Phase 2	Japan
7	JPRN-UMIN000020527	2016/02/01	01/02/2016	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of oral inosine on the onset of wearing off in patients with early stage Parkinson's disease - Randomized clinical trial to assess the disease modifying effect of oral inosine for patients with Parkinson's disease	Parkinson's disease	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years Lactose as a placebo for 2 years	Ehime University Graduate School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	100	Phase 2	Japan
8	NCT00833690 (ClinicalTrials.gov)	June 2009	27/1/2009	Safety of Urate Elevation in Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease	Parkinson Disease	Drug: Placebo;Drug: inosine	The Parkinson Study Group	Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fox Foundation for Parkinson's Research	Completed	30 Years	N/A	All	75	Phase 2	United States

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds. - Effect of febuxostat and inosine on CNS diseases	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
2	NCT00067327 (ClinicalTrials.gov)	February 2002	15/8/2003	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Multiple Sclerosis, Relapsing-Remitting	Drug: Inosine	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	18 Years	60 Years	Both	30	Phase 2	United States

17. Multiple system atrophy

Clinical trials : 119 / Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03403309 (ClinicalTrials.gov)	May 2, 2018	11/1/2018	Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial	Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study)	Multiple System Atrophy	Drug: 1) Inosine 5'-monophosphate;Drug: Placebo	Yonsei University	NULL	Completed	19 Years	75 Years	All	43	Phase 2	Korea, Republic of

122. Superficial siderosis

Clinical trials : 3 / Drugs : 3 - (DrugBank : 2) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04890808 (ClinicalTrials.gov)	May 2023	12/5/2021	Therapeutic Antioxidant Supplementation	Therapeutic Antioxidant Supplementation for Enhancement of Neural Protection From Free-iron Toxicity in Superficial Siderosis	Superficial Siderosis	Dietary Supplement: Inosine;Dietary Supplement: IP6	Superficial Siderosis Research Alliance Inc.	NULL	Not yet recruiting	16 Years	77 Years	All	50	N/A	NULL